| Lymphoma, Follicular
Lunsumio vs Epkinly
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Lunsumio vs Epkinly with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpkinly has a higher rate of injection site reactions vs Lunsumio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epkinly but not Lunsumio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lunsumio
Epkinly
At A Glance
IV infusion
Every 3 weeks
Bispecific CD20xCD3 T-cell engager
SC injection
Every 1-4 weeks
CD20xCD3 bispecific antibody
Indications
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Lymphoma, Follicular Step-up dosing: 1 mg IV (Cycle 1 Day 1), 2 mg (Cycle 1 Day 8), 60 mg (Cycle 1 Day 15), 60 mg (Cycle 2 Day 1), then 30 mg every 3 weeks (Cycles 3+); 21-day cycles; administer as IV infusion over a minimum of 4 hours for initial doses.
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) CRS, fatigue, rash, pyrexia, headache, musculoskeletal pain, cough, pruritus, peripheral neuropathy, edema, diarrhea, nausea, dry skin, upper respiratory tract infection, chills, dizziness, insomnia, abdominal pain, arthralgia, dyspnea, skin exfoliation, urinary tract infection
Serious CRS, infections (sepsis, pneumonia, urinary tract infection, EBV viremia, COVID-19, upper respiratory tract infection), renal insufficiency, pyrexia, tumor flare
Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache
Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS
Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)
Pharmacology
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engaging antibody that binds CD3 on T-cells and CD20 on lymphoma and B-lineage cells, activating T-cells to induce B-cell lysis and cytokine release.
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lunsumio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Epkinly
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lunsumio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Epkinly
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lunsumio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Epkinly
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGenmab Patient Assistance Program: Epkinly
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LunsumioView full Lunsumio profile
EpkinlyView full Epkinly profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.